>1,000 patients who presented with

possible
ACS before and after the introduction
of a
lower di
nted with possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml)
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variabili
al infarc
or myocardial infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS
ic threshold (from 0.20 ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)

using a high-sensitivity troponin

assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
1

lower diagnostic threshold (from 0.20

ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a h
resented with possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible

ACS before and after the introduction

of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with

a low coefficient of variability

(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml

to 0.05 ng/ml) for myocardial

infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The
>1,000 patients who presented with
possible
ACS before and after the introduction
of a
lower diagnostic threshold (from 0.20
ng/ml
to 0.05 ng/ml) for myocardial
infarction (MI)
using a high-sensitivity troponin
assay with
a low coefficient of variability
(<10%).1 The